MedPath

Golidocitinib

Generic Name
Golidocitinib
Drug Type
Small Molecule
Chemical Formula
C25H31N9O2
CAS Number
2091134-68-6
Unique Ingredient Identifier
3BY9Z3M34G

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
2025/06/24
NCT07032532
Phase 2
Not yet recruiting
Sun Yat-sen University
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
2025/05/14
NCT06969612
Phase 1
Recruiting
Peking University Cancer Hospital & Institute
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
2025/05/11
NCT06966154
Phase 1
Recruiting
Fudan University
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
2024/12/18
NCT06739265
Phase 1
Recruiting
Peking Union Medical College Hospital
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
2024/12/13
NCT06733051
Phase 2
Recruiting
Sun Yat-sen University
Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients
2024/11/22
NCT06701344
Phase 2
Not yet recruiting
Ruijin Hospital
A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
2024/11/15
NCT06690671
Phase 1
Not yet recruiting
Shanghai Chest Hospital
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
2024/10/08
NCT06630091
Phase 2
Recruiting
M.D. Anderson Cancer Center
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
2024/08/27
NCT06573138
Phase 2
Not yet recruiting
Ruijin Hospital
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
2024/07/22
NCT06511895
Phase 2
Recruiting
Dizal Pharmaceuticals

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.